Saturday 17 October 2026 Export ALLR’s income statement to Excel — free account

Allarity Therapeutics, Inc.

Allarity Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $320,000.00. In the quarter to June 2026, EPS fell 40.0%, free cash flow grew 53.2% and total debt rose 3.56%, each against the same quarter a year earlier.

0.90 0.07 +8.43%

Follow ALLR

Alert me

Market cap: $13.2M
P/E: 0.0×
Fwd P/E: −1.7×
Dividend yield: —
F-score: n/a
Altman Z: −10.51
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 5.35%

Capital & Financial Ratios $m

Market Cap 13.24

Revenue —

Net Income (12.33)

Free Cash Flow (14.08)

Net Debt (25.56)

Current Ratio 1.11

Debt/Equity 0.40

P/E ratio 0.00

Fwd P/E (1.68)

P/S ratio 0.00

P/B ratio 4.05

Past 5Y EPS Growth —

This Y EPS Growth (2.56%)

Next Y EPS Growth (7.50%)

Next Y revenue growth (98.83%)

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	0	20	15	27
Receivables	1	2	1	1
Inventory	—	—	—	—
Other	0	0	0	0
	2	22	18	32

	2023	2024	2025	Q'26
Payables	8	4	4	4
ST’ Debt	1	1	1	1
Other	3	0	—	0
	14	11	8	29

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	(26.68%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(16.66%)	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	—	—	—	—
’25	—	—	—	—	0
’19	—	—	—	—	0
’18	—	—	—	—	0
’17	—	—	—	—	1

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	(3)	—	—	—
’25	(3)	(5)	(3)	(3)	(15)
’24	(1)	(7)	(5)	(3)	(17)
’23	(3)	(2)	(5)	(2)	(13)
’22	(6)	(4)	(4)	(2)	(17)
’21	(3)	(4)	(4)	(4)	(15)
’20	—	—	(5)	(2)	(7)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(5)	(3)	—	—	—
’25	(3)	(5)	(3)	(3)	(15)
’24	(1)	(7)	(5)	(4)	(18)
’23	(3)	(2)	(5)	(2)	(13)
’22	(6)	(4)	(4)	(2)	(17)
’21	(3)	(4)	(4)	(4)	(15)
’20	—	—	(5)	(2)	(7)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.17)	(0.21)	—	—	—
’25	(0.25)	(0.15)	(0.19)	(0.21)	(0.78)
’24	(664.86)	(3.30)	(7.71)	653.19	(15.65)
’23	(106.43k)	(15.78k)	(1.35k)	192.05k	(6.16k)
’22	(470.40k)	(604.80k)	(571.20k)	(656.37k)	(1.86m)
’21	(0.68)	(1.08)	(0.17)	(2.26)	(4.19)
’20	—	—	(0.40)	(0.01)	(2.03)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	7,204,680.00	177,240.00	240.60	0.90	0.61	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	15,288,000.00	10,800,720.00	394,800.00	334.20	2.35
People
People	Employees	—	—	—	—	—	13	9	6	7	8
	Revenue/emp, $m	0.00	0.00	0.00	0.00	—	0.00	0.00	0.00	0.00	0.04
Income, $m
Income, $m	Revenue	1	1	0	0	—	—	—	—	—	0
	Gross margin, %	(32.44)	(229.64)	(1,839.97)	0.00	0.00	0.00	0.00	—	—	100.00
	EBT	(2)	(4)	(3)	(2)	(6)	(27)	(18)	(12)	(25)	(11)
	EBT margin, %	(245.85)	(521.65)	(989.01)	(15,814.17)	0.00	0.00	0.00	0.00	0.00	(3,509.69)
	Net income	(2)	0	(2)	(2)	(7)	(27)	(16)	(12)	(25)	(11)
	Depreciation	0	0	0	0	0	0	18	0	10	0
Per share, $
Per share, $	Revenue	1.05	1.34	0.39	0.28	0.00	0.00	0.00	0.00	0.00	0.02
	Earnings	(0.06)	(0.16)	(0.06)	(33.98)	(2.03)	(4.19)	(1,856,336.00)	(6,162.16)	(15.65)	(0.78)
	Cash flow	(2.01)	(2.17)	(4.96)	(24.00)	(2.22)	(2.34)	0.00	(3,748.53)	(10.80)	(1.03)
	Capex	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	(0.19)	0.00
	Free cash flow	(2.01)	(2.17)	(4.96)	(24.00)	(2.22)	(2.34)	0.00	(3,748.53)	(10.98)	(1.03)
	Book value	2.74	0.65	27.46	42.93	7.49	2.85	0.00	(809.12)	7.35	0.68
	Shares, m	1	1	1	0	3	6	0	0	2	14
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	—	—	—	—	—	0.00
	P/S	0.00	0.00	0.00	0.00	—	—	—	—	—	0.00
	P/B	2,305,433.40	2,305,433.40	2,305,433.40	2,305,433.40	—	—	—	—	—	1.58
	EV/Sales	0.00	0.00	0.00	0.00	—	—	—	—	—	0.00
	EV/FCF	(5,257,685.33)	(5,257,685.33)	(5,257,685.33)	(5,257,685.33)	—	—	—	—	—	(0.23)
Cash, $m
Cash, $m	Operating cash flow	(1)	(1)	(4)	(1)	(7)	(15)	(17)	(13)	(17)	(15)
	Capex	0	—	0	0	0	—	0	—	0	0
	Free cash flow	(1)	(1)	(4)	(1)	(7)	(15)	(17)	(13)	(18)	(15)
Balance, $m
Balance, $m	Working capital	1	0	(3)	0	(4)	1	(6)	(12)	12	9
	Total debt	—	—	3	0	2	1	4	1	1	1
	Net debt	(1)	(1)	3	0	2	(19)	2	1	(18)	(13)
	Shareholders’ equity	2	0	24	2	24	18	0	(3)	12	10
Returns, %
Returns, %	ROA	(71.91)	(412.00)	(11.35)	(7.41)	(35.88)	(64.18)	(65.60)	(154.63)	(145.77)	(54.91)
	ROIC	0.00	0.00	0.00	0.00	(19.73)	0.00	(1,358.95)	0.00	0.00	0.00
	ROE	(158.64)	(479.08)	(19.21)	(12.09)	(50.05)	(125.13)	(233.39)	886.50	(687.46)	(103.80)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BCDA BioCardia, Inc.	$14.2M	— (loss-making)	— (loss-making)	−93.02% (below 0%: shrinking)	n/m	−5.15% (below 0%: shrinking)	100.00%	0.00%	Compare
RVLP RVL Pharmaceuticals PLC	$14.1M	— (loss-making)	— (loss-making)	−2.25% (below 0%: shrinking)	n/m	−734.24% (below 0%: shrinking)	76.43%	(266.66%)	Compare
LPCN Lipocine Inc.	$13.9M	— (loss-making)	— (loss-making)	−69.48% (below 0%: shrinking)	n/m	−60.56% (below 0%: shrinking)	100.00%	(1,495.11%)	Compare
KTTA Pasithea Therapeutics Corp.	$13.7M	— (loss-making)	— (loss-making)	+1,494.04% (above 0%: growing)	n/m	−21.68% (below 0%: shrinking)	0.00%	0.00%	Compare
ICU SeaStar Medical Holding Corporation	$13.5M	— (loss-making)	— (loss-making)	+81.95% (above 0%: growing)	n/m	+0.43% (above 0%: growing)	91.22%	(616.42%)	Compare
HIND Vyome Holdings, Inc.	$13.4M	0.0×	— (loss-making)	−46.00% (below 0%: shrinking)	n/m	−195.04% (below 0%: shrinking)	43.33%	(3,194.81%)	Compare
ALLR Allarity Therapeutics, Inc.	$13.2M	— (loss-making)	— (loss-making)	—	n/m	+53.22% (above 0%: growing)	100.00%	0.00%
CTXR Citius Pharmaceuticals, Inc.	$12.6M	— (loss-making)	—	—	n/m	−60.50% (below 0%: shrinking)	67.07%	(785.39%)	Compare
CASIF CASI Pharmaceuticals Inc.	$12.4M	— (loss-making)	— (loss-making)	−45.93% (below 0%: shrinking)	n/m	−23,251.69% (below 0%: shrinking)	51.14%	(147.67%)	Compare
Median of peers	$13.6M	—	—	−45.93%	—	−60.53%	71.75%	(441.54%)

All 614 Biotechnology stocks →

Allarity Therapeutics, Inc. (ALLR) key facts

Allarity Therapeutics, Inc. (ALLR) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
Allarity Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $320,000.00.
As of October 16, 2026, ALLR traded at $0.90, a market capitalization of $13.2 million.
Return on equity was −103.8% and debt-to-equity 0.40.
Its Altman Z-score is −10.51 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.